drugset / Press release
Phosplatin Therapeutics receives US FDA Orphan Drug designation for the use of PT-112 in patients with Thymoma and Thymic Carcinoma
2018-10-25 · Promontory Therapeutics Inc. · original promontorytx.com ↗
View designation on FDA.gov
The release as fetched from its publisher. promontorytx.com ↗